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Abstract: Characterisation of the physiologic equine amniotic fluid (AF) 
proteome is a prerequisite to study its changes during diseases and 
discover new biomarkers. The aim of this study was to identify by a 
proteomic approach the most abundant proteins of equine AF. AF samples 
were collected at parturition from 24 healthy mares that delivered 
healthy foals. All samples were subjected to sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) on 4-12% gels. A pool of 
the 24 samples, after SDS-PAGE, was cut in 25 slices, trypsin-digested 
and analysed by mass spectrometry (MS) for protein identification. Mean 
AF protein concentration was 1.96±1.12 g/L. Thirty-four proteins were 
successfully identified by MS and subsequently categorised according to 
Gene Ontology (GO). Twelve proteins (e.g. fibronectin, lumican, 
thrombospondin and fibulin) belonged to or interacted with the 
extracellular matrix (ECM) playing an important role in the development 
of foetal tissues. Most of the remaining proteins were classified as 
transport (e.g. albumin, major allergen Equ c1 and alpha-fetoprotein) 
delivering nutrients, ions and lipids essential for foetal growth and 
development. Among these proteins, major allergen Equ c1 is widely 
studied in human medicine because it induces Ig-E mediated type I 
allergic reaction. The absence of immunoglobulins in equine AF was also 
confirmed. 
 
 
 
 
REVISION NOTE 
 
Animal Reproduction Science 
Ms. No. ANIREP-D-16-6583 
Identification of the most abundant proteins in equine amniotic fluid by a proteomic approach. 
 
 
Dear Editor, 
 
thank you for considering the present paper for publication in Animal Reproduction Science and for 
the opportunity to revise our manuscript.  
 
As you can see in the following pages, we answered all the questions raised by the reviewer.  
Following the reviewer suggestions, some sentences with more details have been added improving 
the clarity and the quality of the manuscript. In particular, more details on the statistical analysis 
performed were added and the discussion section was partially modified.  
 
As requested, the added paragraph/words are written in red. Moreover, we highlighted the deleted 
parts in yellow. We upload two version of the revised manuscript: one with the changes highlighted 
and a second version corrected and edited.  
 
In addition, after an accurate revision of the manuscript, we did also other minor corrections to 
improve the editing according to Animal Reproduction Science author’s guidelines. 
 
 
RESPONSE TO REVIEWER 1 
 
 Reviewer #1: In general, this is a well-written manuscript. However, it is merely descriptive 
and does not follow any hypothesis. Nevertheless, it is based on a sufficient number of 
experimental animals and data appear to be reliable. It is therefore recommended for 
publication after moderate revision. The following points of criticism should be taken into 
account: 
This research can be considered as pure, fundamental research, curiosity-driven and aimed to 
improve our knowledge on the complexity of equine amniotic fluid. The description of its proteome 
in healthy mares is a prerequisite for further investigations focused on specific diseases and/or 
pathologic conditions. 
 
 Information in the abstract is very general, please add some data. 
As suggested by the reviewer, some more data and information have been added. 
 
 In the introduction the authors should explain why they choose to analyze the protein of 
amniotic and not of allantoic fluid.  
As suggested by the reviewer, a sentence explaining the motivation of analysing AF instead of 
allantoic fluid was added. 
 
 Line 63: "and discuss their function" should be deleted. 
As suggested by the reviewer, the words have been deleted.  
 
 Lines 74-75: It is stated that all mares were healthy based on clinical and ultrasonographic 
evaluation. Please add details on which parameters have been accessed at what times 
before and after parturition.  
Revision Note
As suggested by the reviewer, more details on clinical and ultrasonographic evaluation have been 
added. 
 
 Information on statistical analysis is not detailed enough.  
As suggested by the reviewer, more information have been added. Correlation analysis between AF 
total proteins and the other evaluated parameters was added. Nevertheless, to the author opinion, 
since the main objective of the present paper was the characterization/description of the AF 
proteome in healthy samples and it was not a comparison between different experimental groups, 
the statistics are mainly descriptive.  
 
 The discussion does not start properly. It is always annoying for the reader if he/she has to 
deal with limitations of the study and has to wait for the more exciting points of the 
discussion. Please start with the most important results and shift the present beginning of 
the discussion to the end.  
Following the reviewer suggestion, the discussion has been modified, moving the first paragraphs to 
the end of the section. In the author’s opinion the non-depletion of albumin and of the other proteins 
is not a limitation, but a decision driven by the intention to maintain the integrity of the sample.  
 
 The authors refer to the point that protein concentration of amniotic fluid analyzed in the 
present study differs from results of other studies and try to explain this discrepancy by the 
use of different methods. However, also in the present study wide variations were found. 
How can such an "inter-individual variability" be explained. What are the possible 
underlying causes?  
As underlined by the reviewer, the inter-individual variability was quite high. However, to the 
authors knowledge, no publications are present in the literature that evaluate possible source of 
inter-individual variability in AF protein concentration. Therefore, to the authors opinion, the 
possible explanation for the variability reported in the present paper could rely on different pre-
hospitalization factors, such as differences in feed and hydration status and in housing conditions. A 
sentence was added at lines 326-331. 
 
 Lines 221 to 229: The publication by Ottsdottir et al. 2010 (Theriogenology 75 (2011) 1130-
1138) on dynamics of MMP in equine fetal fluids has not been considered. 
As suggested by the reviewer, the citation has been added.  
 
 The conclusion has to be rewritten. At present it is another summary but does not present a 
"take home message" for the reader which would be preferable.   
Following the suggestion of the reviewer the conclusion has been rewritten. However, as previously 
reported, since the study is mainly descriptive, also the “take home message” cannot have a direct 
practical/clinical application. 
 
 Table 1: please add bodyweight of mares and their fetuses  
The requested data have been added. 
 
 All Tables and Figures should "stand alone" with complete descriptions of what is being 
presented as for example mean ± sem, numbers of animals, etc. so that the reader does not 
have to refer to the text.  
As suggested by the reviewer, some more information have been added to the figures and tables 
legends. In legend of figure 1 the sample number of the analysed AF as reported in table 1 was also 
added. We also decided to remove table 2, since the data reported were already present in figure 2. 
However, if the reviewer considers the table as useful we will add it again.   
 
Highlights 
 
 Equine amniotic fluid was preliminary characterised for the first time. 
 SDS-PAGE coupled to MS allowed the identification of the most abundant proteins. 
 The three most abundant proteins were albumin, major allergen Eqc1 and fibronectin. 
 The role of the extracellular matrix component in fetal maturation was highlighted. 
 The importance of transport proteins like alfa-fetoprotein and PLTP was evidenced. 
Highlights (for review)
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Abstract 21 
Characterisation of the physiologic equine amniotic fluid (AF) proteome is a prerequisite to 22 
study its changes during diseases and discover new biomarkers. The aim of this study was to 23 
identify by a proteomic approach the most abundant proteins of equine AF. AF samples were 24 
collected at parturition from 24 healthy mares that delivered healthy foals. All samples were 25 
subjected to sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) on 4-26 
12% gels. A pool of the 24 samples, after SDS-PAGE, was cut in 25 slices, trypsin-digested 27 
and analysed by mass spectrometry (MS) for protein identification. Mean AF protein 28 
concentration was 1.96±1.12 g/L. Thirty-four proteins were successfully identified by MS and 29 
subsequently categorised according to Gene Ontology (GO). Twelve proteins (e.g. 30 
fibronectin, lumican, thrombospondin and fibulin) belonged to or interacted with the 31 
extracellular matrix (ECM) playing an important role in the development of foetal tissues. 32 
Most of the remaining proteins were classified as transport (e.g. albumin, major allergen Equ 33 
c1 and alpha-fetoprotein) delivering nutrients, ions and lipids essential for foetal growth and 34 
development. Among these proteins, major allergen Equ c1 is widely studied in human 35 
medicine because it induces Ig-E mediated type I allergic reaction. The absence of 36 
immunoglobulins in equine AF was also confirmed.  37 
 38 
Keywords 39 
Horse, pregnancy, electrophoresis, proteome. 40 
 41 
 42 
43 
3 
 
Introduction 44 
Amniotic fluid (AF) is a complex dynamic milieu that changes as pregnancy 45 
progresses. AF contains nutrients and growth factors that facilitate foetal growth, provides 46 
mechanical cushioning and antimicrobial effectors to protect the foetus and allows assessment 47 
of foetal maturity and disease (Underwood et al. 2005). In comparison to humans, the 48 
physiology and pathophysiology of foetal fluids in domestic mammals are poorly understood 49 
(Canisso et al. 2015). In horses, some studies have investigated biochemical composition, 50 
particularly enzymes and electrolytes, in AF collected by ultrasound-guided transabdominal 51 
amniocentesis, at delivery or at slaughter (Holdstock et al. 1995; Lyle et al. 2006; Williams et 52 
al. 1993; Zanella et al. 2014). AF was also studied for evaluation of foal’s lung maturity at 53 
birth through lecithin/sphingomyelin ratio and lamellar body count (Castagnetti et al. 2007). 54 
More recently, significantly higher levels of lactate were found in AF collected during 55 
parturition in mares delivering healthy foals (Pirrone et al. 2012). 56 
Unlike the allantoic fluid, equine AF can be easily collected during parturition without 57 
stressing the animal and avoiding any contamination (Castagnetti et al. 2007, Pirrone et al. 58 
2012). As reported in women, the biochemical composition of AF, including proteins, is 59 
primarily representative of the foetal profile and reflects its physiological status (Tong 2013), 60 
thus it could be potentially useful to evaluate the high-risk foal born attended. 61 
Proteomics is a powerful analytical approach providing a profile of proteins present in 62 
a biological sample at a given time. The high potential of this approach has been recently 63 
found to have a major role in different areas of veterinary medicine, from farm (Almeida et al. 64 
2015) to companion (Ferlizza et al. 2015; Miller et al. 2014) animals. Proteomic techniques 65 
have recently been applied to the characterisation of horse amniotic membrane (Galera et al. 66 
2015) and bovine conceptus fluids (Riding et al. 2008), whereas the equine AF proteome 67 
remains uncharacterised. Therefore, the aims of this study were to identify the most abundant 68 
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proteins in equine AF by SDS-PAGE separation followed by mass spectrometry 69 
identification. 70 
 71 
Materials and Methods 72 
Animal selection and data collection 73 
Twenty-four mares admitted for assisted delivery during three breeding seasons at the 74 
S. Belluzzi Equine Perinatology Unit of the Department of Veterinary Medical Sciences, 75 
University of Bologna, were included. The mares were hospitalised at about 310 days of 76 
pregnancy because the owners requested an attended parturition, and remained under 77 
observation for at least 7 days postpartum. They were housed in wide straw bedding boxes 78 
and fed with hay ad libitum and concentrates twice a day. During the day, the mares were 79 
allowed to go to pasture. 80 
All the mares included in the study were healthy based on clinical and 81 
ultrasonographic evaluation. At admission, a complete clinical evaluation, including complete 82 
blood count, serum biochemistry and transrectal ultrasonography, was performed. Severe 83 
maternal illness, uterine discharge, premature lactation, twinning, abnormal foetal 84 
presentation, placenta oedema, and signs of foetal distress were ruled out. During the course 85 
of hospitalisation, mares were clinically evaluated twice a day and by transrectal 86 
ultrasonography every 10 days until parturition. The following ultrasonographic parameters 87 
were evaluated: combined thickness of the uterus and placenta, foetal fluids echogenicity, 88 
foetal activity, and foetal orbital area. Foals were born between 320 and 365 days of 89 
pregnancy by normal delivery, had an Apgar score ≥8 recorded within 5 minutes from birth 90 
(Vaala et al. 2002) and had a normal clinical evaluation during the course of hospitalisation, 91 
including a complete blood count and serum biochemistry at birth and an immunoglobulin G 92 
(IgG) serum concentration ≥800 mg/dL at 18-24 hours of life. 93 
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For each mare, the following data were recorded: breed, age, parity, days of 94 
pregnancy, body weight, length of stage II labour (minutes), and foal’s body weight and 95 
Apgar score. All procedures on the animals were carried out with the approval of the Ethical 96 
Committee, in accordance with DL 116/92, approved by the Ministry of Health (approval 97 
number: n.18/64/11; date of approval 22/02/2011). Oral informed consent was given by the 98 
owners. 99 
 100 
Sample collection 101 
At foaling, a sample of AF was collected from each mare with a 50 mL syringe by 102 
needle puncture of the amniotic sac within few minutes of its appearance through the vulva 103 
during stage II of labour. The AF was then immediately transferred to 5 mL test tubes and 104 
stored at -80°C until SDS-PAGE and protein identification were performed. AF protein 105 
concentration was determined by the Biuret method using bovine serum albumin as standard. 106 
 107 
SDS-PAGE 108 
To optimise protein separation, different protocols were tested including 4-12% and 109 
12% polyacrylamide gels (NuPage/Thermo Fisher Scientific, Waltham, Massachusetts, USA) 110 
in 2-(N-morpholino) propanesulfonic acid buffer (MOPS; NuPage/Thermo Fisher Scientific) 111 
or 2-(N-morpholino) ethanesulfonic acid buffer (MES; NuPage/Thermo Fisher Scientific) 112 
with sodium dodecyl sulphate (SDS). Each AF sample (n=24) was analysed at least twice 113 
with the protocol assuring the best protein separation in our experimental conditions (4-12% 114 
gels, in MOPS buffer). Twenty µg of proteins were loaded for each sample and the gels were 115 
stained with Coomassie G250 compatible with mass spectrometry analysis. After staining, 116 
each gel was digitalised by ChemiDoc
TM
MP (BioRad, Hercules, California, USA) and its 117 
pherogram was obtained using ImageLab 5.2.1 software (BioRad). The software determines 118 
the volume of each protein band through the analysis of the pixel values in the digital image, 119 
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meaning as volume the sum of all the pixels intensities within the band boundaries. The band 120 
volumes are subsequently compared to the entire volume of the lane and the relative 121 
abundances reported in percentage. A pool was prepared by collecting and mixing 50 µg of 122 
protein from each AF (n=24) and analysed twice with the same protocol used for each sample.  123 
 124 
Protein identification by mass spectrometry 125 
The pool lanes were divided manually into 25 slices and subjected to in-gel tryptic 126 
digestion as previously described (Bellei et al. 2013). Digested dried samples were then re-127 
suspended in 97% Water/3% ACN added of 1% formic acid (Buffer A) and analysed by a 128 
Nano LC-CHIP-MS system (ESI-Q-TOF 6520; Agilent Technologies, Santa Clara, 129 
California, USA). Four microliters of each sample were loaded into the system and 130 
transported to the Chip enrichment column (Zorbax C18, 4 mm x 5 μm i.d., Agilent 131 
Technologies) by a capillary pump, with a loading flow of 4 μL/min, using 95% 132 
ACN/5%water added of 0.1% formic acid (buffer B) as mobile phase. Nitrogen was used as 133 
the nebulising gas. A separation column (Zorbax C18, 43 mm x 75 μm i.d., Agilent 134 
Technologies), at flow rate of 0.4 μL, was used for peptide separation.  135 
Since the horse protein database is not well annotated, a broader taxonomy, namely 136 
“all mammals”, was selected for identification to be based on sequence homology. Protein-137 
identification peak lists were generated using the Mascot search engine 138 
(http://mascot.cigs.unimo.it/mascot) against the UniProt database (UniProt.org) specifying the 139 
following parameters: mammalian taxonomy, parent ion tolerance ±20 ppm, MS/MS error 140 
tolerance ±0.12 Da, alkylated cysteine as fixed modification and oxidised methionine as 141 
variable modification, and two potential missed trypsin cleavages, as previously described 142 
(Bertoldi et al., 2013). Proteins with a score >80 or identified with at least two or more 143 
significant sequences were selected. The significant threshold in Mascot searches was set to 144 
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obtain a false discovery rate <5% (5% probability of false match for each protein with a score 145 
above 80).  146 
 147 
Statistical analysis  148 
Data (AF total proteins, mare’s age, mare’s and foal’s body weight, parity, days of 149 
pregnancy, length of stage II labour (minutes), foal’s Apgar score and number of bands) were 150 
analysed with statistical software (R version 2.15.1) and reported as mean ± standard 151 
deviation (SD). Shapiro-Wilk normality test was performed to evaluate data normal 152 
distribution. Pearson coefficient of correlation was calculated between AF total proteins and 153 
the other data recorded for each mare (mare’s age, mare’s and foal’s body weight, parity, days 154 
of pregnancy, length of stage II labour (minutes), foal’s Apgar score and number of bands).  155 
The identified proteins were categorised by biological process, molecular function and 156 
cellular component with Gene Ontology terms according to Gene Ontology (GO) and Human 157 
Protein Reference Database (HPRD). 158 
 159 
Results 160 
Clinical data 161 
Clinical data collected from the 24 mares included in the study are shown in Table 1. Mean 162 
AF total protein concentration was 1.96±1.12 g/L, ranging from 0.36 to 4.16 g/L. No 163 
significant correlation was found between AF protein concentration and the other data 164 
recorded. 165 
 166 
SDS-PAGE and protein identification by mass spectrometry  167 
Representative gel and pherogram of AF are reported in Figure 1A and 1B. The mean 168 
number of bands was 23±1.5. All samples presented a similar pattern characterised by two 169 
clusters of bands: the first with molecular weights (MW) higher than 62 kDa and the second 170 
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with MW lower than 34 kDa. In the middle, very few faint bands were present. Figure 2 171 
reports the relative abundance in percentage of AF protein bands. Out of the 25 slices cut 172 
from the gel (Figure 3), 20 yielded significant results leading to the unambiguous 173 
identification of 34 proteins (Table 2). Serum albumin and major allergen Equ c1 (ALL1) 174 
were the two most abundant proteins, followed by fibronectin, transferrin and haemoglobin; 175 
these five proteins represented >60% of the equine AF proteome. Fibronectin, versican and 176 
albumin were also identified in bands characterised by different MW. 177 
The identified proteins categorised by their molecular function and biological process 178 
according to Gene Ontology (GO) and Human Protein Reference Database (HPRD) are 179 
shown in Table 3 and Figure 4. Most of the proteins were involved in cellular growth and/or 180 
maintenance (38%), transport (26%) and protein metabolism (9%). The vast majority of the 181 
identified proteins were classified as extracellular (79%). 182 
 183 
Discussion 184 
The present paper aimed to explore the complexity of equine AF proteome and to 185 
identify its most abundant proteins. The study was carried out on 24 mares of different breed, 186 
age and parity referred to the Equine Perinatology Unit, and they can be considered 187 
representative of a typical equine hospital population. Therefore, the proteomic profile 188 
described can be considered a useful starting point for further applied studies on the equine 189 
AF proteins.  190 
Most of the 34 proteins identified were involved in cellular growth and maintenance, 191 
transport and protein metabolism reflecting the dynamic biological functions of AF. 192 
Regarding cellular growth and/or maintenance, 12 of the proteins identified belonged to or 193 
interacted with the extracellular matrix (ECM) that plays an important role in the development 194 
of foetal tissues. All these proteins, with the exception of versican and proteoglycan 4, were 195 
also identified in human AF (Cho et al. 2007; Michaels et al. 2007) and/or in equine amniotic 196 
9 
 
membrane (Galera et al. 2015). Among the ECM structural proteins, fibronectin is a 197 
multifunctional glycoprotein known to participate in the organisation of ECM binding to 198 
integrins. During pregnancy, fibronectin is expressed in the junction between maternal and 199 
foetal membranes as well as in the uterus and placenta (Mogami et al. 2013). Lumican, a 200 
member of the family of small leucine-rich proteoglycans, is the major keratan sulphate 201 
proteoglycan of the cornea and is also present in the ECM throughout the body, including 202 
human and equine amniotic membrane (Galera et al. 2015; Kao et al. 2006; Mavrou et al. 203 
2008). Based on its interaction with fibrillar collagen and its ability to modulate cell 204 
proliferation and migration, lumican could play a role in the maturation of foetal tissues 205 
(Mavrou et al. 2008). Regarding the non-structural proteins involved in ECM development 206 
and organisation, thrombospondin and fibulin are regulatory proteins belonging to the group 207 
of the matricellular proteins. These proteins represent a bridge between matrix proteins and 208 
cell surface receptors, or other molecules such as cytokines that can interact with the cell 209 
surface (Bornstein, 1995). They are typically expressed at low levels in adult tissues, but are 210 
strongly expressed during development or following injury or pathology (Morris and 211 
Kyriakides, 2014). Gelsolin is a multifunctional actin regulatory protein involved in 212 
cytoskeleton dynamics and structure. In addition to its role in aiding chemotaxis and 213 
movement of intracellular structures, plasma gelsolin binds to a variety of proinflammatory 214 
and bioactive molecules including fibronectin, platelet activating factor and the bacterial 215 
surface lipids lipoteichoic acid and lipopolysaccharide (Peddada et al. 2012). The role of 216 
gelsolin in AF is still unknown, but it has been suggested to modulate inflammation and 217 
bacterial infections in human AF (Sezen et al. 2009). In association with gelsolin, vinculin is 218 
also a component of the actine cytoskeleton and is involved in integrin-mediated focal 219 
adhesion, cell motility and other cellular functions such as migration, proliferation and 220 
differentiation (Wu et al. 2014). Other proteins interacting with ECM that could play 221 
important roles in the development of foetal tissue are type IV collagenase (MMP2) and 222 
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metalloproteinase inhibitor 1 (TIMP1) belonging to the matrix metalloproteinases (MMPs) 223 
and tissue inhibitors respectively. The MMPs are a family of over 20 enzymes acting on the 224 
ECM components, regulated at different levels via their activators, inhibitors and localization 225 
on the cell surface (Sternlicht and Werb, 2001). The biological functions of these enzymes 226 
and their inhibitors have been widely studied, in particular MMP2 is important for bone 227 
development and angiogenesis regulation and has been identified and studied in plasma and 228 
AF of pregnant women (Anumba et al. 2010; Turner et al. 2014). MMPs activity was also 229 
studied in amniotic and allantoic fluid from mares that delivered live term foals and from 230 
mares with preterm delivery, suggesting that MMPs may have a role as markers for high risk 231 
pregnancy in the mare (Oddsdóttir et al. 2011). 232 
Among transport proteins, albumin, transferrin, alpha-fetoprotein, apolipoprotein A1 233 
and phospholipid transfer protein (PLTP) transport nutrients, ions and lipids essential for 234 
foetal growth and development and have been identified as common components of AF also 235 
in humans (Cho et al. 2007; Michaels et al. 2007). Alpha-fetoprotein is member of the 236 
albuminoid superfamily and is present in the allantoic and amniotic fluids of domestic 237 
animals (Luft et al. 1984; Smith et al. 1979). In mammalian foetuses alpha-fetoprotein is 238 
associated with oestrogen-binding, anti-oxidative properties and immunoregulation (DeMees 239 
et al. 2006;  Mizejewski 2001) and it is highly expressed during early pregnancy by the 240 
equine conceptus (Simpson et al. 2000). In women, AF alpha-fetoprotein is actively 241 
investigated for pathologies such as Down syndrome, trisomies 13 and 18, intra-amniotic 242 
infection, preterm delivery, pre-eclampsia, membrane rupture, and foetoplacental hypoxia 243 
(Cho et al. 2007). Recently, Canisso et al. (2015) confirmed the presence of alpha-fetoprotein 244 
in equine foetal fluids during the third trimester of pregnancy and found increased maternal 245 
plasma concentrations of the protein in mares with experimentally induced placentitis. The 246 
presence of ALL1 in AF is challenging. ALL1 is a glycoprotein of 21.7 kDa belonging to the 247 
family of lipocalins, whose function is to carry small hydrophobic molecules such as 248 
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odorants, steroids and pheromones. This protein is expressed in salivary glands and in the 249 
liver and is highly concentrated in secretory fluids such as saliva and urine as well as in hair 250 
and dander (Botros et al. 2001). ALL1 is widely studied in human medicine because it 251 
induces an IgE-mediated type I allergic reaction in the majority of patients allergic to horses 252 
(Lascombe et al. 2000). The physiological role of this protein is still unknown and to our 253 
knowledge, this is the first study reporting the presence of ALL1 in AF. PLTP is a monomeric 254 
glycoprotein involved in lipid transport, lipoprotein metabolism and lipopolysaccharide 255 
binding. It is ubiquitously expressed in human tissues and is secreted into the plasma, where 256 
its central role has been well established (Albers et al. 2012). PLTP is highly expressed in 257 
lung epithelial cells, and may play a role in surfactant metabolism during foetus lung 258 
development (Brehm et al. 2014).  259 
The proteomic approach applied in the present study led to the successful 260 
identification of the most abundant proteins, even though a few additional points should be 261 
taken into consideration. The first one regards the choice of non-depleting albumin and other 262 
major proteins before electrophoresis and MS identification. Complex biological samples 263 
contain thousands of different protein species, few of them characterised by high abundance 264 
and many others by low or very low abundance. The presence of very high abundance 265 
proteins like albumin and immunoglobulins often hampers the separation and characterisation 266 
of serum and AF proteomes, therefore the depletion of these major components has been 267 
applied in human proteomics (Cho et al. 2007; Michaels et al. 2007). However, this approach 268 
can lead to the loss of some low abundance proteins due to the “sponge effect” of albumin 269 
that can bind a variety of other proteins or peptides (Bellei et al. 2011). From this point of 270 
view, equine AF is a preferential sample due to the absence of immunoglobulins. In domestic 271 
animals, the passage of immunoglobulins is influenced by the placental structure: in horses, 272 
pigs and ruminants the placenta is epitheliochorial, thus impermeable to immunoglobulins 273 
(Furukawa et al. 2014), whereas in dogs, the endotheliochorial placenta allows only 5% to 274 
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10% transfer of maternal antibodies to the foetus (Dall’Ara et al. 2015). From an analytical 275 
point of view, the absence of immunoglobulins in equine AF, as confirmed by this study, can 276 
be considered an advantage, allowing to perform SDS-PAGE and MS identification without 277 
affecting proteome integrity and complexity. 278 
The second point is related to the sample collection. This study collected AF only at 279 
parturition because mares were client-owned and transabdominal amniocentesis is still not 280 
recommended for clinical use. Recently, Canisso et al. (2014) described a safe technique to 281 
perform multiple ultrasound-guided foetal fluid samplings during the last trimester of 282 
gestation in mares. On this basis, abdominal amniocentesis will probably be preferred more 283 
frequently also in a clinical setting and to evaluate gestational changes in the AF proteome as 284 
reported in women (Michaels et al. 2007).  285 
The last point regards AF total protein concentrations, which were similar to those 286 
reported by Williams et al. (1993) (3.1±2.6 g/L) and Paccamonti et al. (1995) (1-2 g/L), but 287 
lower than those reported by Kochhar et al. (1997) (9.1±2 g/L), and higher than those of 288 
Zanella et al. (2014) (0.3±0.1 g/L). The reported discrepancies could be related to the use of 289 
quantification methods characterised by different analytical performances; also the influence 290 
of wide inter-individual variability cannot be excluded. Many environmental and 291 
physiological factors can contribute to this variability; in particular, since the mares were 292 
client-owned, pre-hospitalisation conditions, such as housing, feeding, nutrition and hydration 293 
status, might have affected AF total protein concentration. 294 
 295 
Conclusions 296 
Applying a qualitative proteomic approach, this study identified the 34 most abundant 297 
proteins of the AF proteome from healthy mares that delivered live term foals. GO 298 
categorisation demonstrated that these proteins are involved in different biological processes 299 
and molecular functions including cell growth/maintenance and transport. Some of these 300 
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proteins belonged to or interacted with the extracellular matrix, highlighting the role of its 301 
components in foetal maturation. The study confirmed also the importance of transport 302 
proteins like alpha-fetoprotein and PLTP, and reported for the first time the presence of ALL1 303 
in AF. Though entirely descriptive, these findings can be considered valuable context for 304 
further investigations to gain insights into the function of the proteins identified and to 305 
discover potential biomarkers of foetal disease at birth or during pregnancy.  306 
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Table 1. Clinical data collected from the 24 mares included in the study. Data are reported as 315 
mean ± standard deviation. AF amniotic fluid; TP total proteins. 316 
Sample  Breed Age 
Mare 
weight 
Foal 
weight 
Parity 
Length of 
pregnancy 
Length of 
stage II 
Foal’s 
Apgar 
score 
AF 
TP 
  years Kg Kg  days minutes  g/L 
1 Saddlebred 11 660 51.7 1 355 25 10 2.74 
2 Thoroughbred 6 645 51 1 344 20 10 1.66 
3 Standardbred 5 565 50 2 335 14 8 1.51 
4 Standardbred 6 585 44 1 329 8 8 3.07 
5 Saddlebred 7 660 53 2 330 16 9 2.64 
6 Saddlebred 12 500 40 1 360 20 9 1.01 
7 Saddlebred 17 650 58 3 330 13 9 0.55 
8 Quarter Horse 11 560 42.6 5 333 14 9 0.58 
9 Saddlebred 14 660 53.5 1 354 20 10 0.36 
10 Arabian 5 450 42 2 335 15 10 0.90 
11 Standardbred 7 565 45.3 1 328 11 10 1.39 
12 Standardbred 19 578 43.5 3 349 12 8 1.25 
13 Standardbred 12 546 45 2 352 15 8 1.30 
14 Standardbred 16 590 42.5 11 347 9 8 1.73 
15 Standardbred 10 535 50 6 343 8 10 0.58 
16 Standardbred 14 610 45 6 336 21 9 2.50 
17 Arabian 12 430 50 6 326 20 10 2.29 
18 Standardbred 6 620 59 1 341 18 10 1.66 
19 Standardbred 20 606 45 12 338 12 10 4.01 
20 Saddlebred 16 650 47 2 360 5 8 3.01 
21 Standardbred 18 680 50 4 332 9 9 4.16 
22 Thoroughbred 13 580 58 4 354 12 8 2.14 
23 Quarter Horse 16 425 41 3 357 17 9 4.16 
24 Standardbred 19 660 56 3 345 25 8 1.75 
 
 
12 
± 9.5 
583.8 
± 74.1 
48.7 
± 11.4 
3 
± 3 
342 
± 10.7 
15 
± 5.7 
9 
± 1 
1.96 
± 1.12 
 317 
318 
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Table 2. Proteins identified in equine amniotic fluid by mass spectrometry. Identified proteins 319 
are listed according to the number of the band as marked in Figure 3.  320 
Band
 a
 Entry name 
b
 Protein full name 
MW 
(kDa) 
c
 
Score 
d
 Pept. 
e
 
Sign. 
Pept.
f
 
Seq.
g
 
Sign 
Seq.
h
 
% id.
i
 
1 CSPG2_BOVIN Versican core protein 371.8 257 76 21 15 6 77.2 
2 FINC_HORSE Fibronectin   58.1 1451 155 89 19 18 100 
3 FINC_HORSE Fibronectin   58.1 440 76 34 15 10 100 
4 
FINC_BOVIN Fibronectin  275.5 155 46 16 16 7 95.4 
CO6A1_HUMAN Collagen alpha-1(VI) chain  109.6 168 41 16 10 7 89 
5 VINC_HUMAN Vinculin 124.3 148 53 18 26 10 99.5 
6 
ACE2_PAGLA Angiotensin-converting enzyme 2 93.0 380 43 18 10 6 86 
PLMN_HORSE Plasminogen   38.1 288 36 18 8 5 100 
FINC_CANFA Fibronectin   58.2 148 18 11 7 5 96.4 
7 
GELS_HORSE Gelsolin 81.1 1911 193 122 27 21 100 
FBLN1_HUMAN Fibulin-1  81.3 434 80 47 11 9 91.2 
FINC_HORSE Fibronectin   58.1 360 36 23 11 7 100 
LUM_MOUSE Lumican  38.6 159 27 14 6 4 87.4 
8 
TRFE_HORSE Serotransferrin  80.3 2201 263 153 43 32 100 
TRFL_HORSE Lactotransferrin   77.9 268 61 30 19 11 100 
9 TRFE_HORSE Serotransferrin  80.3 1642 194 106 34 24 100 
10 
ALBU_HORSE Serum albumin 70.5 2863 244 148 44 33 100 
ECM1_HUMAN Extracellular matrix protein 1 62.2 188 53 22 4 4 78.4 
MMP2_BOVIN 72 kDa type IV collagenase  74.8 468 50 27 14 9 95.4 
PLTP_HUMAN Phospholipid transfer protein  54.9 400 24 19 3 3 89.1 
LUM_MOUSE Lumican  38.6 153 23 12 6 4 87.4 
FETA_HORSE Alpha-fetoprotein 70.1 145 17 10 7 4 100 
CSPG2_MACNE Versican core protein   96.8 101 13 7 4 3 82 
11 
ALBU_HORSE Serum albumin 70.5 17663 1154 849 70 56 100 
FETA_HORSE Alpha-fetoprotein  70.1 407 59 34 23 14 100 
CSPG2_MACNE Versican core protein  96.8 347 13 10 5 4 82 
BGH3_HUMAN 
Transforming growth factor-beta-
induced protein ig-h3  
75.3 53 12 6 4 3 92.9 
12 A1AT2_HORSE Alpha-1-antiproteinase 2  47.1 195 11 8 4 2 100 
13 
ALBU_EQUAS Serum albumin  70.5 160 53 13 23 9 98.5 
CLUS_HORSE Clusterin 52.7 453 48 28 15 10 100 
ACTB_BOVIN Actin cytoplasmic 1 42.1 118 36 11 14 6 100 
GELS_HORSE Gelsolin  81.1 40 12 4 7 4 100 
IBP3_BOVIN 
Insulin-like growth factor-binding 
protein  
32.6 79 11 9 5 5 86.7 
FETUA_BOVIN Alpha-2-HS-glycoprotein  39.2 65 11 6 2 2 71.3 
CO6A3_HUMAN Collagen alpha-3(VI) chain  345.2 93 5 4 3 2 88.5 
HPT_BOVIN Haptoglobin  45.6 52 3 2 3 2 78.9 
14 
CLUS_HORSE Clusterin  52.7 42 18 4 7 3 100 
TSP1_BOVIN Thrombospondin-1  133.4 29 13 3 9 3 96.8 
SFTPA_HORSE 
Pulmonary surfactant-associated 
protein A 
26.5 71 4 3 3 2 100 
15 
TSP1_HUMAN Thrombospondin-1  133.3 751 60 49 12 11 98 
ALL1_HORSE Major allergen Equ c 1 21.9 642 58 33 10 8 100 
TIMP1_HORSE Metalloproteinase inhibitor 1  23.7 189 15 7 5 3 100 
16 
ALL1_HORSE Major allergen Equ c 1  21.9 1620 193 107 17 11 100 
TSP1_HUMAN Thrombospondin-1 133.3 351 58 26 13 9 98 
APOA1_CANFA Apolipoprotein A-1  30.2 124 24 11 4 3 80.8 
17 
HBB_HORSE Haemoglobin sub. beta  16.1 2153 159 114 14 12 100 
HBA_HORSE Haemoglobin sub. alpha  15.3 824 87 53 8 7 100 
18 PIP_HYLSY Prolactin-inducible protein homolog 16.9 122 9 8 1 1 64.3 
16 
 
19 THIO_HORSE Thioredoxin  12.0 80 12 2 4 1 100 
20 
PRG4_HUMAN Proteoglycan 4  152.2 130 18 8 3 2 88.6 
ALBU_EQUAS Serum albumin  70.5 75 18 10 4 3 98.5 
a
 Number of the identified band as marked in Figure 3. 321 
b 
Protein entry name from UniProt knowledge database. 322 
c
 Theoretical protein molecular weight. 323 
d
 The highest scores obtained with Mascot search engine. 324 
e
 Peptides: total number of peptides matching the identified proteins. 325 
f
 Significant peptides: total number of significant peptides matching the identified proteins. 326 
g
 Sequence: total number of distinct sequences matching the identified proteins. 327 
h
 Significant sequences: total number of significant distinct sequences matching the identified 328 
proteins. 329 
i
 Percentage of identical amino acids between the identified protein and the respective horse 330 
protein. 331 
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Table 3. Biological and functional classification of the proteins identified in equine amniotic 332 
fluid. Identified proteins are listed according to the Biological Process category. 333 
Entry name 
a
 Protein full name 
MW 
(kDa)
 b
 
Biol. Proc. 
c
 Mol. Funct.
d
 Cell. Comp.
e
 
HPT_BOVIN Haptoglobin 45.6 Acute-phase response HB binding Extracellular 
BGH3_HUMAN 
Transforming growth 
factor-beta-induced protein 
ig-h3  
75.3 
Cell communication/ 
signal transduction 
Receptor binding Extracellular 
CO6A1_HUMAN Collagen alpha-1(VI) chain  109.6 
Cell growth/ 
maintenance 
Extracellular matrix 
structural constituent 
Extracellular 
CO6A3_HUMAN Collagen alpha-3(VI) chain 345.2 
Cell growth/ 
maintenance 
peptidase inhibitor Extracellular 
CSPG2_BOV Versican core protein   371.8 
Cell growth/ 
maintenance 
Extracellular matrix 
structural constituent 
Extracellular 
ECM1_HUMAN 
Extracellular matrix 
protein 1 
62.2 
Cell growth/ 
maintenance 
Extracellular matrix 
structural constituent 
Extracellular 
FBLN1_HUMAN Fibulin-1  81.3 
Cell growth/ 
maintenance 
Extracellular matrix 
structural constituent 
Extracellular 
FINC_HORSE Fibronectin   58.1 
Cell growth/ 
maintenance 
Extracellular matrix 
structural constituent 
Extracellular 
GELS_HORSE Gelsolin 81.1 
Cell growth/ 
maintenance 
Structural constituent of 
cytoskeleton 
Extracellular 
IBP3_BOVIN 
Insulin-like growth factor-
binding protein 
32.6 
Cell growth/ 
maintenance 
protein binding Extracellular 
LUM_MOUSE Lumican  38.6 
Cell growth/ 
maintenance 
Extracellular matrix 
structural constituent 
Extracellular 
PRG4_HUMAN Proteoglycan 4  152.2 
Cell growth/ 
maintenance 
Binding/Cell adhesion 
molecule  
Extracellular 
TIMP1_HORSE 
Metalloproteinase inhibitor 
1  
23.7 
Cell growth/ 
maintenance 
Extracellular matrix 
structural constituent 
Extracellular 
TSP1_HUMAN Thrombospondin-1 133.3 
Cell growth/ 
maintenance 
Extracellular matrix 
structural constituent 
Extracellular 
VINC_HUMAN Vinculin 124.3 
Cell growth/ 
maintenance 
Cytoskeletal protein 
binding 
Cytoplasm 
CLUS_HORSE Clusterin 52.7 
Cell morphogenesis/  
cell death 
protein binding-chaperone Cytoplasm 
THIO_HORSE Thioredoxin  12.0 
Metabolism/ energy 
pathways 
Catalytic activity Cytoplasm 
FETUA_BOVIN Alpha-2-HS-glycoprotein 39.2 Mineral balance protein binding Extracellular 
ACTB_BOVIN Actin cytoplasmic 1 42.1 Protein folding protein binding Cytoskeleton 
ACE2_PAGLA 
Angiotensin-converting 
enzyme 2 
93.0 Protein metabolism Carboxylpeptidase 
Plasma 
membrane 
MMP2_BOVIN 
72 kDa type IV 
collagenase  
74.8 Protein metabolism Metallopeptidase Extracellular 
PLMN_HORSE Plasminogen   38.1 Protein metabolism Peptidase Extracellular 
SFTPA_HORSE 
Pulmonary surfactant-
associated protein A 
26.5 
Respiratory gaseous 
exchange 
carbohydrate/metal ion 
binding 
Extracellular 
ALBU_HORSE Serum albumin 70.5 Transport Transporter  Extracellular 
ALL1_HORSE Major allergen Equ c 1  21.9 Transport Transporter  Extracellular 
APOA1_CANFA Apolipoprotein A-I  30.2 Transport Binding 
Extracellular/ 
HDL 
FETA_HORSE Alpha-fetoprotein 70.1 Transport  Transporter  Extracellular 
HBA_HORSE Haemoglobin subunit alpha  15.3 Transport Transporter  Extracellular 
HBB_HORSE Haemoglobin subunit beta  16.1 Transport Transporter  Extracellular 
PLTP_HUMAN 
Phospholipid transfer 
protein  
54.9 Transport Transporter  Extracellular 
TRFE_HORSE Serotransferrin  80.3 Transport Transporter  Extracellular 
TRFL_HORSE Lactotransferrin   77.9 Transport Transporter  Secretory 
18 
 
granule 
A1AT2_HORSE Alpha-1-antiproteinase 2  47.1 Unknown Protease inhibitor NA 
PIP_HYLSY 
Prolactin-inducible protein 
homolog 
16.9 Unknown Binding Extracellular 
 334 
a
 Protein entry name from UniProt knowledge database. 335 
b
 Theoretical protein molecular weight. 336 
c
 Biological Process according to Gene Ontology and Human Protein Reference Database. 337 
d
 Molecular Function according to Gene Ontology and Human Protein Reference Database. 338 
e
 Cellular Component according to Gene Ontology and Human Protein Reference Database. 339 
 340 
341 
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Figure Legends 342 
Figure 1. Representative SDS-PAGE of 6 out of the 24 amniotic fluid samples on 4-12% gel 343 
in MOPS buffer. Twenty micrograms of proteins were loaded for each lane and the gel was 344 
stained with Coomassie Blue. A) Representative AF samples (lane 1, molecular weight 345 
marker; lanes 2-7, AF collected from six different healthy mares [samples 16-21]); B) 346 
representative pherogram obtained from lane 3  347 
 348 
Figure 2. Relative abundance of each protein band compared to the entire volume of the lane; 349 
data are expressed as percentage (%) and reported as mean ± standard deviation (n=24).  350 
  351 
Figure 3. SDS-PAGE of the amniotic fluid pool on 4-12% gel in MOPS buffer. The pool was 352 
prepared by collecting and mixing 50 µg of proteins from each AF sample (n=24). Two 353 
replicates are reported. Arrows and numbers indicate the slices that have been excised and 354 
analysed by ESI-Q-TOF as listed in Table 2. Asterisk (*) indicates bands that did not give 355 
significant results by MS identification. 356 
 357 
Figure 4. Distribution of amniotic fluid proteins in the Biological process category according 358 
to Gene Ontology (GO) and the Human Protein Reference Database (HPRD) as reported in 359 
Table 3. 360 
 361 
 362 
363 
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Abstract 21 
Characterisation of the physiologic equine amniotic fluid (AF) proteome is a prerequisite to 22 
study its changes during diseases and discover new biomarkers. The aim of this study was to 23 
identify by a proteomic approach the most abundant proteins of equine AF. AF samples were 24 
collected at parturition from 24 healthy mares that delivered healthy foals. All samples were 25 
subjected to sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) on 4-26 
12% gels. A pool of the 24 samples, after SDS-PAGE, was cut in 25 slices, trypsin-digested 27 
and analysed by mass spectrometry (MS) for protein identification. Mean AF protein 28 
concentration was 1.96±1.12 g/L. Thirty-four proteins were successfully identified by MS and 29 
subsequently categorised according to Gene Ontology (GO). Twelve proteins (e.g. 30 
fibronectin, lumican, thrombospondin and fibulin) belonged to or interacted with the 31 
extracellular matrix (ECM) playing an important role in the development of foetal tissues. 32 
Most of the remaining proteins were classified as transport (e.g. albumin, major allergen Equ 33 
c1 and alpha-fetoprotein) delivering nutrients, ions and lipids essential for foetal growth and 34 
development. Among these proteins, major allergen Equ c1 is widely studied in human 35 
medicine because it induces Ig-E mediated type I allergic reaction. The absence of 36 
immunoglobulins in equine AF was also confirmed. The present study successfully applied 37 
SDS-PAGE coupled to MS identifying the most abundant proteins of equine AF, highlighting 38 
the importance of ECM and transport proteins. 39 
 40 
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Introduction 46 
Amniotic fluid (AF) is a complex dynamic milieu that changes as pregnancy 47 
progresses. AF contains nutrients and growth factors that facilitate foetal growth, provides 48 
mechanical cushioning and antimicrobial effectors to protect the foetus and allows assessment 49 
of foetal maturity and disease (Underwood et al. 2005). In comparison to humans, the 50 
physiology and pathophysiology of foetal fluids in domestic mammals are poorly understood 51 
(Canisso et al. 2015). In horses, some studies have investigated biochemical composition, 52 
particularly enzymes and electrolytes, in AF collected by ultrasound-guided transabdominal 53 
amniocentesis, at delivery or at slaughter (Holdstock et al. 1995; Lyle et al. 2006; Williams et 54 
al. 1993; Zanella et al. 2014). AF was also studied for evaluation of foal’s lung maturity at 55 
birth through lecithin/sphingomyelin ratio and lamellar body count (Castagnetti et al. 2007). 56 
More rRecently, significantly higher levels of lactate were found in AF collected during 57 
parturition in mares delivering healthy foals (Pirrone et al. 2012). 58 
Unlike the allantoic fluid, equine AF can be easily collected during parturition without 59 
stressing the animal and avoiding any contamination (Castagnetti et al. 2007, Pirrone et al. 60 
2012). As reported in women, the biochemical composition of AF, including proteins, is 61 
primarily representative of the foetal profile and reflects its physiological status (Tong 2013), 62 
thus it could be potentially useful to evaluate the high-risk foal born attended. 63 
Proteomics is a powerful analytical approach providing a profile of proteins present in 64 
a biological sample at a given time. The high potential of this approach has been recently 65 
found to have a major role in different areas of veterinary medicine, from farm (Almeida et al. 66 
2015) to companion (Ferlizza et al. 2015; Miller et al. 2014) animals. Proteomic techniques 67 
have recently been applied to the characterisation of horse amniotic membrane (Galera et al. 68 
2015) and bovine conceptus fluids (Riding et al. 2008), whereas the equine AF proteome 69 
remains uncharacterised. Therefore, the aims of this study were to identify the most abundant 70 
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proteins in equine AF by SDS-PAGE separation followed by mass spectrometry identification 71 
and discuss their functions. 72 
 73 
Materials and Methods 74 
Animal selection and data collection 75 
Twenty-four mares admitted for assisted delivery during three breeding seasons at the 76 
S. Belluzzi Equine Perinatology Unit of the Department of Veterinary Medical Sciences, 77 
University of Bologna, were included. The mares were hospitalised at about 310 days of 78 
pregnancy because the owners requested an attended parturition, and remained under 79 
observation for at least 7 days postpartum. They were housed in wide straw bedding boxes 80 
and fed with hay ad libitum and concentrates twice a day. During the day, the mares were 81 
allowed to go to pasture. 82 
All the mares included in the study were healthy based on clinical and 83 
ultrasonographic evaluation. At admission, a complete clinical evaluation, including complete 84 
blood count, serum biochemistry and transrectal ultrasonography, was performed. Severe 85 
maternal illness, uterine discharge, premature lactation, twinning, abnormal foetal 86 
presentation, placenta oedema, and signs of foetal distress were ruled out. During the course 87 
of hospitalisation, mares were clinically evaluated twice a day and by transrectal 88 
ultrasonography every 10 days until parturition. The following ultrasonographic parameters 89 
were evaluated: combined thickness of the uterus and placenta, foetal fluids echogenicity, 90 
foetal activity, and foetal orbital area. Foals were born between 320 and 365 days of 91 
pregnancy, by normal delivery, had an Apgar score ≥8 recorded within 5 minutes from birth 92 
(Vaala et al. 2002) and had a normal clinical evaluation during the course of hospitalisation, 93 
including a complete blood count and serum biochemistry at birth and an immunoglobulin G 94 
(IgG) serum concentration ≥800 mg/dL at 18-24 hours of life. 95 
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For each mare, the following data were recorded: breed, age, parity, days of 96 
pregnancy, body weight, length of stage II labour (minutes), and foal’s body weight and 97 
Apgar score. All procedures on the animals were carried out with the approval of the Ethical 98 
Committee, in accordance with DL 116/92, approved by the Ministry of Health (approval 99 
number: n.18/64/11; date of approval 22/02/2011). Oral informed consent was given by the 100 
owners. 101 
 102 
Sample collection 103 
At foaling, a sample of AF was collected from each mare with a 50 mL syringe by 104 
needle puncture of the amniotic sac within few minutes of its appearance through the vulva 105 
during stage II of labour. The AF was then immediately transferred to 5 mL test tubes and 106 
stored at -80°C until SDS-PAGE and protein identification were performed. AF protein 107 
concentration was determined by the Biuret method using bovine serum albumin as standard. 108 
 109 
SDS-PAGE 110 
To optimise protein separation, different protocols were tested including 4-12% and 111 
12% polyacrylamide gels (NuPage/Thermo Fisher Scientific, Waltham, Massachusetts, USA) 112 
in 2-(N-morpholino) propanesulfonic acid buffer (MOPS; NuPage/Thermo Fisher Scientific) 113 
or 2-(N-morpholino) ethanesulfonic acid buffer (MES; NuPage/Thermo Fisher Scientific) 114 
with sodium dodecyl sulphate (SDS). Each AF sample (n=24) was analysed at least twice 115 
with the protocol assuring the best protein separation in our experimental conditions (4-12% 116 
gels, in MOPS buffer). Twenty µg of proteins were loaded for each sample and the gels were 117 
stained with Coomassie G250 compatible with mass spectrometry analysis. After staining, 118 
each gel was digitalised by ChemiDoc
TM
MP (BioRad, Hercules, California, USA) and its 119 
pherogram was obtained using ImageLab 5.2.1 software (BioRad). The software determines 120 
the volume of each protein band through the analysis of the pixel values in the digital image, 121 
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meaning as volume the sum of all the pixels intensities within the band boundaries. The band 122 
volumes are subsequently compared to the entire volume of the lane and the relative 123 
abundances reported in percentage. A pool was prepared by collecting and mixing 50 µg of 124 
protein from each AF (n=24) and analysed twice with the same protocol used for each sample.  125 
 126 
Protein identification by mass spectrometry 127 
The pool lanes were divided manually into 25 slices and subjected to in-gel tryptic 128 
digestion as previously described (Bellei et al. 2013). Digested dried samples were then re-129 
suspended in 97% Water/3% ACN added of 1% formic acid (Buffer A) and analysed by a 130 
Nano LC-CHIP-MS system (ESI-Q-TOF 6520; Agilent Technologies, Santa Clara, 131 
California, USA). Four microliters of each sample were loaded into the system and 132 
transported to the Chip enrichment column (Zorbax C18, 4 mm x 5 μm i.d., Agilent 133 
Technologies) by a capillary pump, with a loading flow of 4 μL/min, using 95% 134 
ACN/5%water added of 0.1% formic acid (buffer B) as mobile phase. Nitrogen was used as 135 
the nebulising gas. A separation column (Zorbax C18, 43 mm x 75 μm i.d., Agilent 136 
Technologies), at flow rate of 0.4 μL, was used for peptide separation.  137 
Since the horse protein database is not well annotated, a broader taxonomy, namely 138 
“all mammals”, was selected for identification to be based on sequence homology. Protein-139 
identification peak lists were generated using the Mascot search engine 140 
(http://mascot.cigs.unimo.it/mascot) against the UniProt database (UniProt.org) specifying the 141 
following parameters: mammalian taxonomy, parent ion tolerance ±20 ppm, MS/MS error 142 
tolerance ±0.12 Da, alkylated cysteine as fixed modification and oxidised methionine as 143 
variable modification, and two potential missed trypsin cleavages, as previously described 144 
(Bertoldi et al., 2013). Proteins with a score >80 or identified with at least two or more 145 
significant sequences were selected. The significant threshold in Mascot searches was set to 146 
7 
 
obtain a false discovery rate <5% (5% probability of false match for each protein with a score 147 
above 80).  148 
 149 
Statistical analysis  150 
Data (AF total proteins, mare’s age, mare’s and foal’s body weight, parity, days of 151 
pregnancy, length of stage II labour (minutes), foal’s Apgar score and number of bands) were 152 
analysed with statistical software (R version 2.15.1) and reported as mean ± standard 153 
deviation (SD). Shapiro-Wilk normality test was performed to evaluate data normal 154 
distribution. Pearson coefficient of correlation was calculated between AF total proteins and 155 
the other data recorded for each mare (mare’s age, mare’s and foal’s body weight, parity, days 156 
of pregnancy, length of stage II labour (minutes), foal’s Apgar score and number of bands).  157 
The identified proteins were categorised by biological process, molecular function and 158 
cellular component with Gene Ontology terms according to Gene Ontology (GO) and Human 159 
Protein Reference Database (HPRD). 160 
 161 
Results 162 
Clinical data 163 
Clinical data collected from the 24 mares included in the study are shown in Table 1. Mean 164 
AF total protein concentration was 1.96±1.12 g/L, ranging varied from 0.36 to 4.16 g/L. No 165 
significant correlations were found between AF protein concentration and the other data 166 
recorded. 167 
 168 
SDS-PAGE and protein identification by mass spectrometry  169 
Representative gel and pherogram of AF are reported in Figure 1A and 1B. The mean 170 
number of bands was 23±1.5. All samples presented a similar pattern characterised by two 171 
clusters of bands: the first with molecular weights (MW) higher than 62 kDa and the second 172 
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with MW lower than 34 kDa. In the middle, very few faint bands were present. Figure 2 and 173 
Table 2 reports the relative abundance in percentage of AF protein bands. Out of the 25 slices 174 
cut from the gel (Figure 3), 20 yielded significant results leading to the unambiguous 175 
identification of 34 proteins (Table 2 3). Serum albumin and major allergen Equ c1 (ALL1) 176 
were the two most abundant proteins, followed by fibronectin, transferrin and haemoglobin; 177 
these five proteins represented >60% of the equine AF proteome. Fibronectin, versican and 178 
albumin were also identified in bands characterised by different MW. 179 
The identified proteins categorised by their molecular function and biological process 180 
according to Gene Ontology (GO) and Human Protein Reference Database (HPRD) are 181 
shown in Table 3 4 and Figure 4. Most of the proteins were involved in cellular growth and/or 182 
maintenance (38%), transport (26%) and protein metabolism (9%). The vast majority of the 183 
identified proteins were classified as extracellular (79%). 184 
 185 
Discussion 186 
The present paper aimed to explore the complexity of equine AF proteome and to 187 
identify its most abundant proteins. Since this The study was carried out on 24 mares of 188 
different breeds, age and parity referred to the Equine Perinatology Unit, the animals were of 189 
different breed, age and parity, and they can be considered representative of a typical equine 190 
hospital population reflecting the local equine population. Therefore, the proteomic profile 191 
described can be considered a useful starting point for further applied studies on the equine 192 
AF proteins.  193 
 This study collected AF at parturition because mares were client-owned and 194 
transabdominal amniocentesis is still not recommended for clinical use. Recently, Canisso et 195 
al. (2014) described a safe technique to perform multiple ultrasound-guided foetal fluid 196 
samplings during the last trimester of gestation in mares. On this basis, abdominal 197 
amniocentesis will probably be preferred more frequently also in a clinical setting and to 198 
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evaluate gestational changes in the AF proteome as in women (Michaels et al. 2007). 199 
Regarding total proteins, values found in the present research (1.96±1.12 g/L) are similar to 200 
those reported by Williams et al. (1993) (3.1±2.6 g/L) and Paccamonti et al. (1995) (1-2 g/L), 201 
but lower than those reported by Kochhar et al. (1997) (9.1±2 g/L) and higher than those of  202 
Zanella et al. (2014) (0.3±0.1 g/L). The use of different methods for AF total proteins 203 
quantification or the wide inter-individual variability in concentration could be the cause of 204 
the reported discrepancies. 205 
Complex biological samples contain thousands of different protein species, few of 206 
them characterised by high abundance and many others by low or very low abundance. The 207 
presence of very high abundance proteins like albumin or immunoglobulins often hampers the 208 
separation and characterisation of serum and AF proteomes, therefore the depletion of these 209 
major components has been widely applied in human proteomics (Cho et al. 2007; Michaels 210 
et al. 2007). However, this approach can lead to the loss of some low abundance proteins due 211 
to the “sponge effect” of albumin that can bind a variety of other proteins or peptides (Bellei 212 
et al. 2011). From this point of view, equine AF is a preferential sample due to the absence of 213 
immunoglobulins. In domestic animals, the passage of immunoglobulins is influenced by the 214 
placental structure: in horses, pigs and ruminants the placenta is epitheliochorial, thus 215 
impermeable to immunoglobulins (Furukawa et al. 2014), whereas in dogs, the 216 
endotheliochorial placenta allows only 5% to 10% transfer of maternal antibodies to the 217 
foetus (Dall’Ara et al. 2015). The absence of immunoglobulins in equine AF, as confirmed by 218 
this study, was advantageous for its more reliable characterisation, as a consequence to 219 
preserve proteome integrity and complexity the most abundant proteins were not depleted. 220 
Most of the 34 proteins identified were involved in cellular growth and maintenance, 221 
transport and protein metabolism reflecting the dynamic biological functions of AF. 222 
Regarding cellular growth and/or maintenance, 12 of the proteins identified belonged to or 223 
interacted with the extracellular matrix (ECM) that plays an important role in the development 224 
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of foetal tissues. All these proteins, with the exception of versican and proteoglycan 4, were 225 
also identified in human AF (Cho et al. 2007; Michaels et al. 2007) and/or in equine amniotic 226 
membrane (Galera et al. 2015). Among the ECM structural proteins, fibronectin is a 227 
multifunctional glycoprotein known to participate in the organisation of ECM binding to 228 
integrins. During pregnancy, fibronectin is expressed in the junction between maternal and 229 
foetal membranes as well as in the uterus and placenta (Mogami et al. 2013). Lumican, a 230 
member of the family of small leucine-rich proteoglycans, is the major keratan sulphate 231 
proteoglycan of the cornea and is also present in the ECM throughout the body, including 232 
human and equine amniotic membrane (Galera et al. 2015; Kao et al. 2006; Mavrou et al. 233 
2008). Based on its interaction with fibrillar collagen and its ability to modulate cell 234 
proliferation and migration, lumican could play a role in the maturation of foetal tissues 235 
(Mavrou et al. 2008). Regarding the non-structural proteins involved in ECM development 236 
and organisation, thrombospondin and fibulin are regulatory proteins belonging to the group 237 
of the matricellular proteins. These proteins represent a bridge between matrix proteins and 238 
cell surface receptors, or other molecules such as cytokines that can interact with the cell 239 
surface (Bornstein, 1995). They are typically expressed at low levels in adult tissues, but are 240 
strongly expressed during development or following injury or pathology (Morris and 241 
Kyriakides, 2014). Gelsolin is a multifunctional actin regulatory protein involved in 242 
cytoskeleton dynamics and structure. In addition to its role in aiding chemotaxis and 243 
movement of intracellular structures, plasma gelsolin binds to a variety of proinflammatory 244 
and bioactive molecules including fibronectin, platelet activating factor and the bacterial 245 
surface lipids lipoteichoic acid and lipopolysaccharide (Peddada et al. 2012). The role of 246 
gelsolin in AF is still unknown, but it has been suggested to modulate inflammation and 247 
bacterial infections in human AF (Sezen et al. 2009). In association with gelsolin, vinculin is 248 
also a component of the actine cytoskeleton and is involved in integrin-mediated focal 249 
adhesion, cell motility and other cellular functions such as migration, proliferation and 250 
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differentiation (Wu et al. 2014). Other proteins interacting with ECM that could play 251 
important roles in the development of foetal tissue are type IV collagenase (MMP2) and 252 
metalloproteinase inhibitor 1 (TIMP1) belonging to the matrix metalloproteinases (MMPs) 253 
and tissue inhibitors respectively. The MMPs are a family of over 20 enzymes acting on the 254 
ECM components, regulated at different levels via their activators, inhibitors and localization 255 
on the cell surface (Sternlicht and Werb, 2001). The biological functions of these enzymes 256 
and their inhibitors have been widely studied, in particular MMP2 is important for bone 257 
development and angiogenesis regulation and has been identified and studied in plasma and 258 
AF of pregnant women (Anumba et al. 2010; Turner et al. 2014). MMPs activity was also 259 
studied in amniotic and allantoic fluid from mares that delivered live term foals and from 260 
mares with preterm delivery, suggesting that MMPs may have a role as markers for high risk 261 
pregnancy in the mare (Oddsdóttir et al. 2011). 262 
Among transport proteins, albumin, transferrin, alpha-fetoprotein, apolipoprotein A1 263 
and phospholipid transfer protein (PLTP) transport nutrients, ions and lipids essential for 264 
foetal growth and development and have been identified as common components of AF also 265 
in humans (Cho et al. 2007; Michaels et al. 2007). Alpha-fetoprotein is member of the 266 
albuminoid superfamily, and is present in the allantoic fluid and AF amniotic fluids of 267 
domestic animals (Luft et al. 1984; Smith et al. 1979). In mammalian foetuses alpha-268 
fetoprotein is associated with oestrogen-binding, anti-oxidative properties and 269 
immunoregulation (DeMees et al. 2006;  Mizejewski 2001) and In horses, alpha-fetoprotein it 270 
is highly expressed during early pregnancy by the equine conceptus (Simpson et al. 2000) and 271 
in mammalian foetuses, it is associated with estrogen-binding, anti-oxidative properties and 272 
immunoregulation (DeMees et al. 2006;  Mizejewski 2001). In women, AF alpha-fetoprotein 273 
is actively investigated for pathologies such as Down syndrome, trisomies 13 and 18, intra-274 
amniotic infection, preterm delivery, pre-eclampsia, membrane rupture, and foetoplacental 275 
hypoxia (Cho et al. 2007). Recently, Canisso et al. (2015) confirmed the presence of alpha-276 
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fetoprotein in equine foetal fluids during the third trimester of pregnancy and found increased 277 
maternal plasma concentrations of the protein in mares with experimentally induced 278 
placentitis. The presence of ALL1 in AF is challenging. ALL1 is a glycoprotein of 21.7 kDa 279 
belonging to the family of lipocalins, whose function is to carry small hydrophobic molecules 280 
such as odorants, steroids and pheromones. This protein is expressed in salivary glands and in 281 
the liver and is highly concentrated in secretory fluids such as saliva and urine as well as in 282 
hair and dander (Botros et al. 2001). ALL1 is widely studied in human medicine because it 283 
induces an IgE-mediated type I allergic reaction in the majority of patients allergic to horses 284 
(Lascombe et al. 2000). The physiological role of this protein is still unknown and to our 285 
knowledge, this is the first study reporting the presence of ALL1 in AF. PLTP is a monomeric 286 
glycoprotein involved in lipid transport, lipoprotein metabolism and lipopolysaccharide 287 
binding. It is ubiquitously expressed in human tissues and is secreted into the plasma, where 288 
its central role has been well established (Albers et al. 2012). PLTP is highly expressed in 289 
lung epithelial cells, and may play a role in surfactant metabolism during foetus lung 290 
development (Brehm et al. 2014).  291 
The proteomic approach applied in the present study led to the successful 292 
identification of the most abundant proteins, even though a few additional points should be 293 
taken into consideration. The first one regards the choice of non-depleting albumin and other 294 
major proteins before electrophoresis and MS identification. Complex biological samples 295 
contain thousands of different protein species, few of them characterised by high abundance 296 
and many others by low or very low abundance. The presence of very high abundance 297 
proteins like albumin and immunoglobulins often hampers the separation and characterisation 298 
of serum and AF proteomes, therefore the depletion of these major components has been 299 
applied in human proteomics (Cho et al. 2007; Michaels et al. 2007). However, this approach 300 
can lead to the loss of some low abundance proteins due to the “sponge effect” of albumin 301 
that can bind a variety of other proteins or peptides (Bellei et al. 2011). From this point of 302 
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view, equine AF is a preferential sample due to the absence of immunoglobulins. In domestic 303 
animals, the passage of immunoglobulins is influenced by the placental structure: in horses, 304 
pigs and ruminants the placenta is epitheliochorial, thus impermeable to immunoglobulins 305 
(Furukawa et al. 2014), whereas in dogs, the endotheliochorial placenta allows only 5% to 306 
10% transfer of maternal antibodies to the foetus (Dall’Ara et al. 2015). From an analytical 307 
point of view, the absence of immunoglobulins in equine AF, as confirmed by this study, was 308 
advantageous for its more reliable characterisation, as a consequence to preserve proteome 309 
integrity and complexity the most abundant proteins were not depleted. can be considered an 310 
advantage, allowing to perform SDS-PAGE and MS identification without affecting proteome 311 
integrity and complexity. 312 
The second point is related to the sample collection. This study collected AF only at 313 
parturition because mares were client-owned and transabdominal amniocentesis is still not 314 
recommended for clinical use. Recently, Canisso et al. (2014) described a safe technique to 315 
perform multiple ultrasound-guided foetal fluid samplings during the last trimester of 316 
gestation in mares. On this basis, abdominal amniocentesis will probably be preferred more 317 
frequently also in a clinical setting and to evaluate gestational changes in the AF proteome as 318 
reported in women (Michaels et al. 2007).  319 
The last point regards Regarding AF total protein concentrations, which values found 320 
in the present research (1.96±1.12 g/L) with a wide variability (range 0.36-4.16 g/L) are were 321 
similar to those reported by Williams et al. (1993) (3.1±2.6 g/L) and Paccamonti et al. (1995) 322 
(1-2 g/L), but lower than those reported by Kochhar et al. (1997) (9.1±2 g/L), and higher than 323 
those of Zanella et al. (2014) (0.3±0.1 g/L). The use of different methods for AF total proteins 324 
quantification or the wide inter-individual variability in concentration could be the cause of 325 
the reported discrepancies. The reported discrepancies could be related to the use of 326 
quantification methods characterised by different analytical performances; also the influence 327 
of wide inter-individual variability cannot be excluded. Many environmental and 328 
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physiological factors can contribute to this variability; in particular, since the mares were 329 
client-owned, pre-hospitalisation conditions, such as housing, feeding, nutrition and hydration 330 
status, might have affected AF total protein concentration. 331 
 332 
Conclusions 333 
Applying a qualitative proteomic approach, this study identified the 34 most abundant 334 
proteins of the AF proteome from healthy mares that delivered live term foals The present 335 
applyied a qualitative proteomic approach to characterise the AF proteome from healthy 336 
mares. The 34 proteins identified GO categorisation demonstrated that these proteins are 337 
involved in different biological processes and molecular functions including cell 338 
growth/maintenance and transport. Some of these proteins belonged to or interacted with the 339 
extracellular matrix, highlighting the role of its the ECM components in foetal maturation. 340 
The study confirmed also the importance of transport proteins like alpha-fetoprotein and 341 
PLTP, and reported for the first time the presence of ALL1 in AF. Further studies are needed 342 
to define reference intervals for AF total protein in healthy mares and Though entirely 343 
descriptive, these findings can be considered valuable context for further investigations to 344 
gain insights into the function of the proteins identified and to discover potential biomarkers 345 
of foetal disease at birth or during pregnancy. In particular, 2DE could be applied to better 346 
characterise the physiologic AF proteome and to evaluate differentially expressed proteins in 347 
case of disease.  348 
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Table 1. Clinical data collected from the 24 mares included in the study. Data are reported as 357 
mean ± standard deviation. AF amniotic fluid; TP total proteins. 358 
Sample  Breed Age 
Mare 
weight 
Foal 
weight 
Parity 
Length of 
pregnancy 
Length of 
stage II 
Foal’s 
Apgar 
score 
AF 
TP 
  years Kg Kg  days minutes  g/L 
1 Saddlebred 11 660 51.7 1 355 25 10 2.74 
2 Thoroughbred 6 645 51 1 344 20 10 1.66 
3 Standardbred 5 565 50 2 335 14 8 1.51 
4 Standardbred 6 585 44 1 329 8 8 3.07 
5 Saddlebred 7 660 53 2 330 16 9 2.64 
6 Saddlebred 12 500 40 1 360 20 9 1.01 
7 Saddlebred 17 650 58 3 330 13 9 0.55 
8 Quarter Horse 11 560 42.6 5 333 14 9 0.58 
9 Saddlebred 14 660 53.5 1 354 20 10 0.36 
10 Arabian 5 450 42 2 335 15 10 0.90 
11 Standardbred 7 565 45.3 1 328 11 10 1.39 
12 Standardbred 19 578 43.5 3 349 12 8 1.25 
13 Standardbred 12 546 45 2 352 15 8 1.30 
14 Standardbred 16 590 42.5 11 347 9 8 1.73 
15 Standardbred 10 535 50 6 343 8 10 0.58 
16 Standardbred 14 610 45 6 336 21 9 2.50 
17 Arabian 12 430 50 6 326 20 10 2.29 
18 Standardbred 6 620 59 1 341 18 10 1.66 
19 Standardbred 20 606 45 12 338 12 10 4.01 
20 Saddlebred 16 650 47 2 360 5 8 3.01 
21 Standardbred 18 680 50 4 332 9 9 4.16 
22 Thoroughbred 13 580 58 4 354 12 8 2.14 
23 Quarter Horse 16 425 41 3 357 17 9 4.16 
24 Standardbred 19 660 56 3 345 25 8 1.75 
 
 
12 
± 9.5 
583.8 
± 74.1 
48.7 
± 11.4 
3 
± 3 
342 
± 10.7 
15 
± 5.7 
9 
± 1 
1.96 
± 1.12 
 359 
360 
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Table 2. Relative abundance in percentage of each protein band compared to the entire 361 
volume of the lane (n=24).  362 
 363 
MW 
(kDa) 
Mean 
(%) 
SD  
 (%) 
>165 0.3 0.2 
>165 1.5 0.4 
>165 5.2 1.9 
>165 1.4 0.3 
145 0.3 0.2 
131 0.1 0.1 
117 0.6 0.1 
102 0.6 0.2 
91 0.7 0.2 
83 3.6 0.7 
73 2.0 0.9 
64 25.7 2.8 
53 1.4 0.5 
41 1.4 0.5 
35 0.7 0.2 
29 1.6 0.5 
24 19.2 3.6 
21 0.7 0.2 
18 4.2 1.2 
14 3.0 2.9 
<13 3.4 1.0 
<13 2.8 1.2 
<13 4.0 0.8 
 364 
365 
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Table 2 3. Proteins identified in equine amniotic fluid by mass spectrometry. Identified 366 
proteins are listed according to the number of the band as marked in Figure 3.  367 
Band
 a
 Entry name 
b
 Protein full name 
MW 
(kDa) 
c
 
Score 
d
 Pept. 
e
 
Sign. 
Pept.
f
 
Seq.
g
 
Sign 
Seq.
h
 
% id.
i
 
1 CSPG2_BOVIN Versican core protein 371.8 257 76 21 15 6 77.2 
2 FINC_HORSE Fibronectin   58.1 1451 155 89 19 18 100 
3 FINC_HORSE Fibronectin   58.1 440 76 34 15 10 100 
4 
FINC_BOVIN Fibronectin  275.5 155 46 16 16 7 95.4 
CO6A1_HUMAN Collagen alpha-1(VI) chain  109.6 168 41 16 10 7 89 
5 VINC_HUMAN Vinculin 124.3 148 53 18 26 10 99.5 
6 
ACE2_PAGLA Angiotensin-converting enzyme 2 93.0 380 43 18 10 6 86 
PLMN_HORSE Plasminogen   38.1 288 36 18 8 5 100 
FINC_CANFA Fibronectin   58.2 148 18 11 7 5 96.4 
7 
GELS_HORSE Gelsolin 81.1 1911 193 122 27 21 100 
FBLN1_HUMAN Fibulin-1  81.3 434 80 47 11 9 91.2 
FINC_HORSE Fibronectin   58.1 360 36 23 11 7 100 
LUM_MOUSE Lumican  38.6 159 27 14 6 4 87.4 
8 
TRFE_HORSE Serotransferrin  80.3 2201 263 153 43 32 100 
TRFL_HORSE Lactotransferrin   77.9 268 61 30 19 11 100 
9 TRFE_HORSE Serotransferrin  80.3 1642 194 106 34 24 100 
10 
ALBU_HORSE Serum albumin 70.5 2863 244 148 44 33 100 
ECM1_HUMAN Extracellular matrix protein 1 62.2 188 53 22 4 4 78.4 
MMP2_BOVIN 72 kDa type IV collagenase  74.8 468 50 27 14 9 95.4 
PLTP_HUMAN Phospholipid transfer protein  54.9 400 24 19 3 3 89.1 
LUM_MOUSE Lumican  38.6 153 23 12 6 4 87.4 
FETA_HORSE Alpha-fetoprotein 70.1 145 17 10 7 4 100 
CSPG2_MACNE Versican core protein   96.8 101 13 7 4 3 82 
11 
ALBU_HORSE Serum albumin 70.5 17663 1154 849 70 56 100 
FETA_HORSE Alpha-fetoprotein  70.1 407 59 34 23 14 100 
CSPG2_MACNE Versican core protein  96.8 347 13 10 5 4 82 
BGH3_HUMAN 
Transforming growth factor-beta-
induced protein ig-h3  
75.3 53 12 6 4 3 92.9 
12 A1AT2_HORSE Alpha-1-antiproteinase 2  47.1 195 11 8 4 2 100 
13 
ALBU_EQUAS Serum albumin  70.5 160 53 13 23 9 98.5 
CLUS_HORSE Clusterin 52.7 453 48 28 15 10 100 
ACTB_BOVIN Actin cytoplasmic 1 42.1 118 36 11 14 6 100 
GELS_HORSE Gelsolin  81.1 40 12 4 7 4 100 
IBP3_BOVIN 
Insulin-like growth factor-binding 
protein  
32.6 79 11 9 5 5 86.7 
FETUA_BOVIN Alpha-2-HS-glycoprotein  39.2 65 11 6 2 2 71.3 
CO6A3_HUMAN Collagen alpha-3(VI) chain  345.2 93 5 4 3 2 88.5 
HPT_BOVIN Haptoglobin  45.6 52 3 2 3 2 78.9 
14 
CLUS_HORSE Clusterin  52.7 42 18 4 7 3 100 
TSP1_BOVIN Thrombospondin-1  133.4 29 13 3 9 3 96.8 
SFTPA_HORSE 
Pulmonary surfactant-associated 
protein A 
26.5 71 4 3 3 2 100 
15 
TSP1_HUMAN Thrombospondin-1  133.3 751 60 49 12 11 98 
ALL1_HORSE Major allergen Equ c 1 21.9 642 58 33 10 8 100 
TIMP1_HORSE Metalloproteinase inhibitor 1  23.7 189 15 7 5 3 100 
16 
ALL1_HORSE Major allergen Equ c 1  21.9 1620 193 107 17 11 100 
TSP1_HUMAN Thrombospondin-1 133.3 351 58 26 13 9 98 
APOA1_CANFA Apolipoprotein A-1  30.2 124 24 11 4 3 80.8 
17 
HBB_HORSE Haemoglobin sub. beta  16.1 2153 159 114 14 12 100 
HBA_HORSE Haemoglobin sub. alpha  15.3 824 87 53 8 7 100 
18 PIP_HYLSY Prolactin-inducible protein homolog 16.9 122 9 8 1 1 64.3 
19 THIO_HORSE Thioredoxin  12.0 80 12 2 4 1 100 
19 
 
20 
PRG4_HUMAN Proteoglycan 4  152.2 130 18 8 3 2 88.6 
ALBU_EQUAS Serum albumin  70.5 75 18 10 4 3 98.5 
a
 Number of the identified band as marked in Figure 3. 368 
b 
Protein entry name from UniProt knowledge database. 369 
c
 Theoretical protein molecular weight. 370 
d
 The highest scores obtained with Mascot search engine. 371 
e
 Peptides: total number of peptides matching the identified proteins. 372 
f
 Significant peptides: total number of significant peptides matching the identified proteins. 373 
g
 Sequence: total number of distinct sequences matching the identified proteins. 374 
h
 Significant sequences: total number of significant distinct sequences matching the identified 375 
proteins. 376 
i
 Percentage of identical amino acids between the identified protein and the respective horse 377 
protein. 378 
20 
 
Table 3 4. Biological and functional classification of the proteins identified in equine 379 
amniotic fluid. Identified proteins are listed according to the Biological Process category. 380 
Entry name 
a
 Protein full name 
MW 
(kDa)
 b
 
Biol. Proc. 
c
 Mol. Funct.
d
 Cell. Comp.
e
 
HPT_BOVIN Haptoglobin 45.6 Acute-phase response HB binding Extracellular 
BGH3_HUMAN 
Transforming growth 
factor-beta-induced protein 
ig-h3  
75.3 
Cell communication/ 
signal transduction 
Receptor binding Extracellular 
CO6A1_HUMAN Collagen alpha-1(VI) chain  109.6 
Cell growth/ 
maintenance 
Extracellular matrix 
structural constituent 
Extracellular 
CO6A3_HUMAN Collagen alpha-3(VI) chain 345.2 
Cell growth/ 
maintenance 
peptidase inhibitor Extracellular 
CSPG2_BOV Versican core protein   371.8 
Cell growth/ 
maintenance 
Extracellular matrix 
structural constituent 
Extracellular 
ECM1_HUMAN 
Extracellular matrix 
protein 1 
62.2 
Cell growth/ 
maintenance 
Extracellular matrix 
structural constituent 
Extracellular 
FBLN1_HUMAN Fibulin-1  81.3 
Cell growth/ 
maintenance 
Extracellular matrix 
structural constituent 
Extracellular 
FINC_HORSE Fibronectin   58.1 
Cell growth/ 
maintenance 
Extracellular matrix 
structural constituent 
Extracellular 
GELS_HORSE Gelsolin 81.1 
Cell growth/ 
maintenance 
Structural constituent of 
cytoskeleton 
Extracellular 
IBP3_BOVIN 
Insulin-like growth factor-
binding protein 
32.6 
Cell growth/ 
maintenance 
protein binding Extracellular 
LUM_MOUSE Lumican  38.6 
Cell growth/ 
maintenance 
Extracellular matrix 
structural constituent 
Extracellular 
PRG4_HUMAN Proteoglycan 4  152.2 
Cell growth/ 
maintenance 
Binding/Cell adhesion 
molecule  
Extracellular 
TIMP1_HORSE 
Metalloproteinase inhibitor 
1  
23.7 
Cell growth/ 
maintenance 
Extracellular matrix 
structural constituent 
Extracellular 
TSP1_HUMAN Thrombospondin-1 133.3 
Cell growth/ 
maintenance 
Extracellular matrix 
structural constituent 
Extracellular 
VINC_HUMAN Vinculin 124.3 
Cell growth/ 
maintenance 
Cytoskeletal protein 
binding 
Cytoplasm 
CLUS_HORSE Clusterin 52.7 
Cell morphogenesis/  
cell death 
protein binding-chaperone Cytoplasm 
THIO_HORSE Thioredoxin  12.0 
Metabolism/ energy 
pathways 
Catalytic activity Cytoplasm 
FETUA_BOVIN Alpha-2-HS-glycoprotein 39.2 Mineral balance protein binding Extracellular 
ACTB_BOVIN Actin cytoplasmic 1 42.1 Protein folding protein binding Cytoskeleton 
ACE2_PAGLA 
Angiotensin-converting 
enzyme 2 
93.0 Protein metabolism Carboxylpeptidase 
Plasma 
membrane 
MMP2_BOVIN 
72 kDa type IV 
collagenase  
74.8 Protein metabolism Metallopeptidase Extracellular 
PLMN_HORSE Plasminogen   38.1 Protein metabolism Peptidase Extracellular 
SFTPA_HORSE 
Pulmonary surfactant-
associated protein A 
26.5 
Respiratory gaseous 
exchange 
carbohydrate/metal ion 
binding 
Extracellular 
ALBU_HORSE Serum albumin 70.5 Transport Transporter  Extracellular 
ALL1_HORSE Major allergen Equ c 1  21.9 Transport Transporter  Extracellular 
APOA1_CANFA Apolipoprotein A-I  30.2 Transport Binding 
Extracellular/ 
HDL 
FETA_HORSE Alpha-fetoprotein 70.1 Transport  Transporter  Extracellular 
HBA_HORSE Haemoglobin subunit alpha  15.3 Transport Transporter  Extracellular 
HBB_HORSE Haemoglobin subunit beta  16.1 Transport Transporter  Extracellular 
PLTP_HUMAN 
Phospholipid transfer 
protein  
54.9 Transport Transporter  Extracellular 
TRFE_HORSE Serotransferrin  80.3 Transport Transporter  Extracellular 
TRFL_HORSE Lactotransferrin   77.9 Transport Transporter  Secretory 
21 
 
granule 
A1AT2_HORSE Alpha-1-antiproteinase 2  47.1 Unknown Protease inhibitor NA 
PIP_HYLSY 
Prolactin-inducible protein 
homolog 
16.9 Unknown Binding Extracellular 
 381 
a
 Protein entry name from UniProt knowledge database. 382 
b
 Theoretical protein molecular weight. 383 
c
 Biological Process according to Gene Ontology and Human Protein Reference Database. 384 
d
 Molecular Function according to Gene Ontology and Human Protein Reference Database. 385 
e
 Cellular Component according to Gene Ontology and Human Protein Reference Database. 386 
 387 
388 
22 
 
Figure Legends 389 
Figure 1. Representative SDS-PAGE of 6 out of the 24 amniotic fluid samples on 4-12% gel 390 
in MOPS buffer. Twenty micrograms of proteins were loaded for each lane and the gel was 391 
stained with Coomassie Blue. A) Representative AF samples (lane 1, molecular weight 392 
marker; lanes 2-7, AF collected from six different healthy mares [samples 16-21]); B) 393 
representative pherogram obtained from of lane 3  394 
 395 
Figure 2. Relative abundance in percentage of each protein band compared to the entire 396 
volume of the lane; data are expressed as percentage (%) and reported as mean ± standard 397 
deviation (n=24).  398 
  399 
Figure 3. SDS-PAGE of the amniotic fluid pool on 4-12% gel in MOPS buffer. Two 400 
replicates of the pool was prepared by collecting and mixing 50 µg of proteins from each AF 401 
sample (n=24). Two replicates are reported. Arrows and numbers indicate the slices that have 402 
been excised and analysed by ESI-Q-TOF as listed in Table 2 3. Asterisk (*) indicates bands 403 
that did not give significant results by MS identification. 404 
 405 
Figure 4. Distribution of amniotic fluid proteins in the Biological process category according 406 
to Gene Ontology (GO) and the Human Protein Reference Database (HPRD) as reported in 407 
Table 3. 408 
 409 
 410 
411 
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